Accounts payable and accrued expenses consisted of the following at June 30, 2026 and December 31, 2025 (in thousands):


	As of June 30, 2026		As of December 31, 2025
Accounts payable:
Clinical and regulatory expenses	$	409	$	565
Professional fees		501		927
Selling expenses		2,028		1,721
Manufacturing costs		191		1,466
Non-employee director compensation		1,011		1,018
Other vendors		208		282
Total accounts payable		4,348		5,979
Accrued interest payable, related parties		1,652		1,474
Accrued interest payable		7,522		5,841
Accrued expenses:
Payroll expenses		346		452
Government rebates and other rebates		9,342		8,538
Other accrued expenses		256		331
Total accrued expenses		9,944		9,321
Total accounts payable and accrued expenses	$	23,466	$	22,615

Other current liabilities consisted of the following at June 30, 2026 and December 31, 2025 (in thousands):


	As of June 30, 2026		As of December 31, 2025
Trade discount	$	3,300	$	3,190
Unearned revenue (a)		11,197		13,000
Other current liabilities		1,171		1,375
Total other current liabilities	$	15,668	$	17,565

(a) Refer to Note 3 for further information.

Other long-term liabilities consisted of the following at June 30, 2026 and December 31, 2025 (in thousands):


	As of June 30, 2026		As of December 31, 2025
Trade discount	$	10,580	$	12,239
Unearned Revenue		2,244		—
Other long-term liabilities		60		53
Total other long-term liabilities	$	12,884	$	12,292

On June 12, 2017, the Company entered into an API Supply Agreement with Telcon pursuant to which Telcon advanced to the Company approximately $31.8 million as an advance trade discount in consideration of the Company’s agreement to purchase from Telcon the Company’s estimated annual target for bulk containers of PGLG. On July 12, 2017, the Company entered into a raw material supply agreement with Telcon which revised certain items of the API Supply Agreement (the “revised API Agreement”). The Company did not purchase PGLG from Telcon for six months ended June 30, 2026 and 2025. $6,000 and $1.1 million of accounts payable were included in the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025. The revised API Agreement provided for an annual API purchase target of $5 million and a target “profit” (i.e., gross margin) to Telcon of $2.5 million. To the extent these targets are not met, which management refers to as a “target shortfall,” Telcon may be entitled to payment of the target shortfall or to settle the target shortfall by exchange of principal and interest on the Telcon convertible bond and proceeds thereof that are pledged as collateral to secure the Company’s obligations under the API Supply Agreement and the revised API Agreement. See Note 5 for information regarding the settlement of the target shortfall.